Sign in

CIK 0001590877

  • Non-accelerated filer
  • Smaller reporting company

REGENXBIO Inc.

Sign in to watch
Ticker
RGNX
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Entity type
Operating
EIN
471851754
Phone
+1 240-552-8181
Business address
9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD, 20850
Former names
ReGenX Biosciences, LLC
  1. 4 Grant or award Director acquired 4,790 shares (grant or award)
  2. 4 Grant or award Director acquired 4,790 shares (grant or award)
  3. 4 Grant or award Director acquired 4,790 shares (grant or award)
  4. 4 Grant or award Director acquired 4,790 shares (grant or award)
  5. 4 Grant or award Director acquired 4,790 shares (grant or award)
  6. 4 Grant or award Director acquired 4,790 shares (grant or award)
  7. 4 Grant or award Director acquired 4,790 shares (grant or award)
  8. 4 Grant or award Director acquired 4,790 shares (grant or award)
  9. 4 Planned sale President and CEO sold 15,000 shares at $15.81 ($237,222)
  10. 4 Planned sale President and CEO sold 15,000 shares at $18.19 ($272,871)
  11. 4 Exercise or conversion Chief Financial Officer acquired 20,041 shares (option exercise)
  12. 4 Planned sale President and CEO sold 15,000 shares at $21.86 ($327,942)
  13. 4 Planned sale Chief Medical Officer sold 12,878 shares at $28.36 ($365,220)
  14. 4 Planned sale President and CEO sold 15,000 shares at an average $16.76 ($251,349)
  15. 4 Planned sale President and CEO sold 45,000 shares at $15.18 ($682,992)
  16. 4 Shares withheld for taxes Chief Oper. & Tech. Officer gave up 8,120 shares (to pay taxes)
  17. 4 Planned sale Chief Medical Officer sold 17,237 shares at $17.39 ($299,789)
  18. 4 Shares withheld for taxes Chief Scientific Officer gave up 8,410 shares (to pay taxes)
  19. 4 Shares withheld for taxes Chief Financial Officer gave up 4,534 shares (to pay taxes)
  20. 4 Shares withheld for taxes President and CEO gave up 11,357 shares (to pay taxes)

Page 5 of 22 · 435 filings